Promoted Content

Promoted Content

All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

ABL Bio

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of

Post An Enquiry

CPhI India 2021

Participation Not Confirmed

Update your events

HiFiBiO Therapeutics Announces a Global Strategic Partnership with ABL Bio for the Co-Development of a SARS-CoV-2 Neutralizing Antibody

Contact the Supplier

Lead Product(s): HFB30132A

Therapeutic Area: Infections and Infectious Diseases Product Name: HFB30132A

Highest Development Status: IND Enabling Product Type: Large molecule

Partner/Sponsor/Collaborator: HiFiBiO Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership September 14, 2020

Details:

Partnership with ABL Bio supports HiFiBiO Therapeutics' rapid clinical advancement of its SARS-CoV-2 neutralizing antibody, HFB30132A, for the treatment of COVID-19 patients.